Arcturus Therapeutics Holdings Inc. (ARCT) vs Opus Genetics, Inc. (IRD)

Arcturus Therapeutics Holdings Inc. and Opus Genetics, Inc. are both Biotechnology companies. Arcturus Therapeutics Holdings Inc. and Opus Genetics, Inc. are of similar size ($412.4M and $405.2M). Opus Genetics, Inc. grew revenue faster over the last twelve months: −36.1% against −76.0%. Arcturus Therapeutics Holdings Inc. has the higher net margin (−317.6% vs −1,091.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Arcturus Therapeutics Holdings Inc. leads on 8 and Opus Genetics, Inc. on 6.

Valuation

Metric ARCT IRD Biotechnology median
P/E n/m n/m 7.88
P/S 13.40 46.11 11.47
P/B 2.29 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 7.54 40.67 10.73
Earnings yield (23.90%) (27.10%) (28.84%)
Free cash flow yield (18.49%) (9.30%) (23.03%)

Profitability

Metric ARCT IRD Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (348.32%) (513.47%) 0.00%
Net margin (317.61%) (1,091.82%) 0.00%
Free cash flow margin (247.79%) (412.61%) 0.00%
Return on equity (46.31%) (4,796.52%) (57.72%)
Return on assets (34.96%) (163.50%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ARCT IRD Biotechnology median
Revenue growth (TTM) (75.95%) (36.09%) 5.64%
EPS growth (last fiscal year) 20.00% 62.79% —
Revenue growth, 5-year CAGR 53.78% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARCT IRD Biotechnology median
Debt to equity 0.00 (2.69) 0.00
Current ratio 5.88 12.19 4.73
Net debt to EBITDA 3.15 1.17 0.96

Dividend

Metric ARCT IRD Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARCT IRD Biotechnology median
Market cap 412.41m 405.16m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack